“Latest Stem Cells News”

Ciaran Finn-Lynch, who became the first child in the world to undergo a groundbreaking trachea transplant in March this year, is set to return home to Northern Ireland.

Ciaran underwent the transplant, which involved the removal of his own trachea replaced by a donor windpipe, at Great Ormond Street Hospital. Doctors then used Ciaran’s own stem cells from inside his body to build up the donor windpipe and ensure the organ was not rejected.

Four weeks ago, doctors were able to describe the transplant as a success for the first time after proving vascular supply had returned to the trachea.

Colleen and Paul, Ciaran’s parents, said: “We cannot thank all the staff involved in Ciaran’s transplant enough. When they initially suggested the procedure we agreed to it, knowing it would be the first time it had been tried in a child, as we have 100 per cent faith in them and the work they do. They were the best people in the world to treat our son.

“Ciaran has undergone some major operations in his life, even prior to this transplant in March. He is resilient and has kept his spirits up throughout. Two weeks ago he had a music lesson while he was on the intensive care unit, he played on the drums and he absolutely loved it. Ciaran’s spirit has never waned.

“We are obviously also incredibly grateful and indebted to Ciaran’s donor and are aware of the heartbreak that family went through in losing someone. They have displayed courage and selflessness and we would like to use this opportunity to urge people to think about signing up to the organ donor register.”

In a major achievement, the scientists have managed to get a patent for growing stem cells of the cornea. The cells will be grown on a synthetic material, called Mebiol Gel, which will be used in the process of transplant.

For a long time scientists across the world have been trying to get the patent. The declaration was made by the researchers at Sankara Nethralaya and Nichi-In Biosciences Sankara Nethralaya and Nichi-In Biosciences on Friday.

The new procedures have been devised and patented by these two institutes. A synthetic substance was used by the researchers for growing the corneal limbal stem cells in order to reduce the chances of viral infections. Moreover, biological materials have a greater chance of rejection.

Dozens of people who were blinded or otherwise suffered severe eye damage when they were splashed with caustic chemicals had their sight restored with transplants of their own stem cells — a stunning success for the burgeoning cell-therapy field, Italian researchers reported Wednesday.

The treatment worked completely in 82 of 107 eyes and partially in 14 others, with benefits lasting up to a decade so far. One man whose eyes were severely damaged more than 60 years ago now has near-normal vision.

“This is a roaring success,” said ophthalmologist Dr. Ivan Schwab of the University of California, Davis, who had no role in the study — the longest and largest of its kind.

Stem cell transplants offer hope to the thousands of people worldwide every year who suffer chemical burns on their corneas from heavy-duty cleansers or other substances at work or at home.

The approach would not help people with damage to the optic nerve or macular degeneration, which involves the retina. Nor would it work in people who are completely blind in both eyes, because doctors need at least some healthy tissue that they can transplant.

Nerve stem cell transplants may help slow the progression of macular degeneration, the most common cause of blindness in the developed world, U.S. researchers said on Monday.

They said putting nerve stem cells from StemCells Inc near the retinas of rats with a form of macular degeneration helped keep the disease from advancing to blindness for several months.

“These cells improve the chemical environment in the back of the eye,” said Ray Lund of the Casey Eye Institute at Oregon Health & Science University in Portland, whose findings were presented at the Society for Neuroscience meeting in Chicago.

Lund said the mechanism is not clear, but he suspects that when immature nerve cells are placed near the retina, they produce growth factors that protect the cells from damage by the disease.

A technique that combines nanotechnology with adult stem cells appears to destroy atherosclerotic plaque and rejuvenate the arteries, according to a study reported at the American Heart Association‘s Basic Cardiovascular Sciences 2010 Scientific Sessions – Technological and Conceptual Advances in Cardiovascular Disease.

In the study, nanoparticles (microscopic particles with at least one dimension less than 80 nm) were infused into the heart of pigs along with adult stem cells. After the nanoparticles were heated by laser light, they burned away arterial plaque. However, nanoparticles were less effective at eliminating plaque if not combined with adult stem cells.

“This unique approach holds promise for use in humans for acute care and urgent restoration of blood flow,” said Alexandr Kharlamov, M.D., lead author and research manager at the Department of Internal Medicine and Research Center of Regenerative Medicine, Ural State Medical Academy in Yekaterinburg, Russian Federation. “Biophotonics (light therapy), plasmonics (plasma therapy), stem cell therapy and nanotechnology might someday offer a completely novel treatment to reduce artery plaque build-up.”

NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, today announced that it has been awarded a $700,000 contract from the U.S. Army Medical Research and Materiel Command, Telemedicine and Advanced Technology Research Center (USAMRMC-TATRC) under U.S. Army Medical Research Acquisition Activity contract number: (W81XWH-10-2-0039).

This contract is for the purpose of evaluating the use of topically applied bone marrow-derived adult mesenchymal stem cells (MSCs) for rapid wound healing. The Company previously announced that this funding was included in the Department of Defense FY09 Appropriations Bill and will begin receiving funds to initiate the program in 2010.

“NeoStem is thrilled to have the United States Government’s support to advance our technology and is honored to become part of TATRC’s regenerative medicine portfolio. It is our goal with this important project to leverage adult stem cell technology to help our soldiers avoid amputations and immobilization from injuries that they may sustain while fighting for our country.